SARASOTA, Fla., Jan. 19 /PRNewswire-FirstCall/ -- Industrial Biotechnology Corporation today announced that N. Gary Howell, Ph.D. has joined the company as Vice President of Business Development.
Dr. Howell has overseen and led diverse businesses within consumer products, biotechnology, R&D, technology transfer, and financial services. He has held leadership roles in organizations ranging from start-ups to Fortune 500 corporations with responsibilities in technology assessment, strategy development, market research and business development.
Prior to joining IBTY, Dr. Howell served as Director of the Cincinnati Center for Clinical Research and Head of Venture Development at Cincinnati Children’s Hospital Medical Center; interim CEO of Genomatix (now Intrexon), a biotechnology company; and while at Procter & Gamble served as Manager of Ph.D./M.D. Recruiting and various Analytical Chemistry and Technology/Product Development departments.
Dr. Howell holds several degrees, including: a Ph.D. and M.S. in Chemistry from Cornell University and a B.S. in Chemistry, cum laude, from the State University of New York College at Cortland. In addition, his association memberships have included: the Association of University Technology Managers, American Chemical Society, American Association for the Advancement of Science and Sigma Xi.
Dr. Howell stated: “I am excited and honored to join Industrial Biotechnology Corporation and serve in this strategic business development role. I am especially pleased to be part of this extremely talented team of bio-scientists and business experts committed to the commercialization of this innovative technology. Our biological production methods, based on our exclusive intellectual property, give us a distinct competitive advantage. Our technologies and production systems are well positioned to exploit the tremendous growth trends taking place today in biotechnology. My focus will be to develop relationships and distribution channels within the Food and Beverage Industry, Flavor and Fragrance Companies, and fine chemical manufacturers, to align their needs with the potentially thousands of chemicals we are able to produce biologically.”
Dave West, Director and CFO, stated, “Gary is a great addition to our team. His knowledge and experience in the chemical industry combined with his executive experience in Fortune 500 companies such as Procter & Gamble, make him an excellent fit to develop the partnerships we need for distribution and sales.”
About Industrial Biotechnology Corporation
Industrial Biotechnology Corporation (IBC) commercializes proprietary technologies and intellectual property in the emerging field of biologically produced chemicals. We believe these technologies enable IBC to more efficiently manufacture high-value chemicals at significantly lower costs, with a substantially lower environmental impact than traditional methods, and with a higher purity. Through licensing, partnerships, and direct sales via multiple distribution channels to several industries, IBC will bring to market new and established chemicals that are in high demand for use in Flavors and Fragrances, Fine chemicals, Pharmaceutical, Agricultural, Environmental and Bio-Energy applications. IBC’s pioneering and state-of-the-art biological production methods can replace large manufacturing facilities, many of which employ hazardous processes and toxic materials in their chemical production. These innovative methods involve fewer production steps, and through the use of “designer” enzymes and proprietary production systems, may enable IBC to produce greater yields of high-purity, natural compounds at significantly lower costs. We believe these processes can be readily scaled up to large, commercial production levels. IBC’s core intellectual property utilizes patented technologies exclusively licensed from Rice University. The company has assembled a team of leading scientists and management and industry leaders to implement these new technologies. IBC has a comprehensive technology and licensing acquisition strategy, and will seek to establish research and development partnerships with leading universities and corporations in the industrial biotechnology field to develop commercially viable biological-based solutions and related intellectual property patents. For more information about Industrial Biotechnology Corporation, please visit its website at http://www.industrialbiotechnology.com .
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements.” These forward-looking statements can generally be identified as such because the context of the statement will include words, such as Industrial Biotechnology Corp. “expects,” “should,” “believes,” “anticipates” or words of similar import. Similarly, statements that describe Industrial Biotechnology Corp.'s future plans, objectives or goals are also forward- looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Industrial Biotechnology Corp., as appropriate, which could cause actual results to differ materially from those currently anticipated. Although Industrial Biotechnology Corp. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed below. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and Industrial Biotechnology Corp. does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Industrial Biotechnology Corporation
CONTACT: David West, Industrial Biotechnology Corporation, +1-941-925-2500
Web site: http://www.industrialbiotechnology.com/
